Loading...
Loading...
ImmunoGen
IMGN, today announced that Novartis
NVS has
licensed the exclusive right to use the Company's antibody-drug
conjugate (ADC) technology to develop anticancer therapeutics to an
undisclosed target. This is the third license to be taken by Novartis –
and the fifth to be taken by a major healthcare company – this year.
“In the past year, Novartis, Eli Lilly and Amgen have each licensed
exclusive rights to use our industry-leading ADC technology for one or
more targets,” commented Daniel Junius, President and CEO. “There are
now numerous highly promising product candidates in the clinic through
our own programs and through our partnerships, with many earlier-stage
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in